Drugs / ZEP-3
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01863160 | Jul 2013 → Jan 2014 | — | Shulov Innovate for Science Ltd. 2012 | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02483182 | Sep 2015 → Jun 2018 | herpes labialis | Shulov Innovate for Science Ltd. 2012 | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZEP-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01863160 ↗ |
| Modality | Peptide | “novel synthetic peptide” NCT01863160 ↗ |
| Route | Topical | “The IP ZEP-3 cream will be applied on both ventral forearms” NCT01863160 ↗ |